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Abstract
Purpose Some of the synthetic cannabinoids, often found in recreational drugs of the herbal form, reportedly induce a 
generalized seizure in drug abusers immediately after smoking. However, it is still unclear what elicits the sensorimotor 
responses, particularly in the case of hyperreflexia or excitatory behavior during the synthetic cannabinoid exposure. The 
purpose of this study was to explore the mechanism underlying the hyperreflexia induced by smoke intoxication of XLR-11 
[(1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone].
Methods Locomotor activity and body temperature of mice were measured using an implanted Nano-Tag device. The inten-
sity of catalepsy was determined by the bar test. The extracellular dopamine levels in the nucleus accumbens and glutamate 
levels in the hippocampus were measured by in vivo microdialysis using electrochemical detector-coupled high-performance 
liquid chromatography and by in vivo enzyme-based biosensor method, respectively.
Results Mice exposed to the smoke of XLR-11 exhibited hyperreflexia at the very early phase, followed by hypothermia 
and catalepsy. The XLR-11 smoke contained XLR-11 and XLR-11 degradant at a ratio of approximately 1:25. Mice treated 
intraperitoneally with XLR-11 degradant at a dose comparable to the smoke inhalation experiment showed a hyperreflexic 
effect immediately after the treatment, but XLR-11 showed no such effect. The effects of XLR-11 degradant were significantly 
suppressed by pretreatment with AM-251, a  CB1 receptor antagonist. Extracellular dopamine and glutamate levels showed 
no evidence of involvement in the XLR-11 degradant-induced hyperreflexia; on the other hand gabapentin, a GABAergic 
antiepileptic, significantly suppressed the enhanced locomotor activity.
Conclusions The hyperreflexic effect of XLR-11 degradant is mediated by the  CB1 receptor and possibly by GABAergic 
function.
Keywords Synthetic cannabinoid · XLR-11 degradant · Microdialysis · Hyperreflexia · CB1 receptor · GABAergic function
Introduction
Since July 2014, when the crackdown on illegal drugs was 
strengthened by the decision to implement emergency meas-
ures to eradicate recreational drug abuse, all head shops sell-
ing such drugs in Japan have been closed. However, rec-
reational drugs are still available through the Internet, and 
drug abuse has remained a serious social problem. Although 
the biological actions of these recreational drugs are poorly 
elucidated, some studies have attempted to clarify their psy-
choactive effects by intraperitoneal administration in animals 
[1, 2], but this does not reflect the actual abuse situation.
Synthetic cannabinoid drugs are available in vari-
ous forms, such as bath salts and herbal incense. The 
herbal incense form, taken mainly by smoking [3], is 
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particularly popular among young abusers [4]. XLR-11 
[(1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcy-
clopropyl)methanone] is a synthetic cannabinoid and was 
found in recreational drugs of the herbal form [3] until 
around 2012, when it began being regulated globally [5].
XLR-11 has a cyclopropyl ring structure and is easily 
cleaved into a pyrolyzed compound, the so-called XLR-11 
degradant, upon heating [6]. XLR-11 is reported to change 
its chemical structure to that of XLR-11 degradant by smok-
ing [7]. However, no study has been published on the psy-
choactive effects of XLR-11 smoke or the XLR-11 degra-
dant. The psychoactive effects of synthetic cannabinoids are 
mediated mainly through the  CB1 receptor and generally 
include analgesia, hypothermia, and suppressed behavior. 
However, a person who abused a recreational drug prod-
uct containing synthetic cannabinoids was found to show 
apparent excitatory behavior such as significant agitation 
and seizures [8].
We have reported that forced  CB1 receptor activation 
was linked with the jumping induced by a pyrolyzed com-
pound of UR-144, another synthetic cannabinoid possess-
ing a cyclopropyl ring, in mice [9]. Reportedly, dopamine 
(DA) is involved in the synthetic cannabinoid JWH-250- and 
JWH-073-induced sensorimotor, neurological, and neuro-
chemical responses, including seizures and aggressiveness, 
in mice [10]. Glutamate has been suggested to be involved 
in synthetic cannabinoid AM-2201-induced seizures [11]. 
Therefore, the excitatory action of synthetic cannabinoids 
may vary, and the mechanisms of action could differ. Our 
preliminary experiments indicated that XLR-11 was more 
potent than UR-144 in mice exposed to the smoke of these 
compounds. Accordingly, this study was designed to clarify 
the mechanism of excitatory action induced by synthetic 
cannabinoids with the cyclopropyl ring using XLR-11. We 
show that mice exposed to the pyrolyzed XLR-11 degradant 
produced by smoking exhibited abnormal behavior, includ-
ing hyperreflexia, in a  CB1-dependent manner, indicating 
that smoking of synthetic cannabinoids may increase senso-
rimotor effects including seizures and hyperreflexia.
Materials and methods
Materials
The research collaborator obtained XLR-11 (Fig.  1a), 
intended for use as an ingredient in the recreational drug 
product, from a recreational drug vendor in April 2012, 
before it was assigned the status of designated substance and 
subsequently classified as a narcotic substance by the Japa-
nese government. The chemical structure of the compound 
was confirmed by nuclear magnetic resonance (ECX-500; 
JEOL, Tokyo, Japan) (NMR) analyses (Fig. S1a). The purity 
of the compound was estimated to be more than 95% by 
1H-NMR. A 50-mg portion of XLR-11 was dissolved in ace-
tone and mixed with 1 g of cut mint leaves. The solvent was 
evaporated to obtain the simulated herbal-type drug con-
taining 5% XLR-11. The XLR-11 degradant (Fig. 1b) was 
made by heating XLR-11 in a sealed glass tube at 300 °C 
for 10 min [9]. NMR analysis indicated that the compound 
obtained by heating was identical to the XLR-11 degradant 
and its content was more than 95% (Fig. S1b). AM-251 
and SCH23390 were purchased from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan); sulpiride and midazolam 
from Astellas Pharma Inc. (Tokyo, Japan); gabapentin from 
Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan); butor-
phanol tartrate from Meiji Seika Pharma Co., Ltd. (Tokyo, 
Japan); medetomidine hydrochloride from Nippon Zenyaku 
Kogyo Co., Ltd. (Fukushima, Japan); SIB1757 from Merck 
KGaA (Darmstadt, Germany).
Animals
Male 8-week-old BALB/c mice were obtained from San-
kyo Lab Service Corporation (Tokyo, Japan). Mice were 
housed in plastic cages placed in a temperature-controlled 
room (22 ± 1 °C) and maintained on a 12-h light–dark cycle 
with free access to food and water.
Fig. 1  Chemical structures of XLR-11 (a), XLR-11 degradant (b), 
UR-144 (c) and UR-144 degradant (d)
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Smoke exposure
The mice were placed in a Multipurpose Inhalation Cage 
unit (7018  cm3, Shibata Biotechnology, Tokyo, Japan) 
(Fig. 2). A 0.5-g portion of mint herb containing XLR-11 or 
mint herb without XLR-11 (control) was burned in the pipe 
connected to the inhalation cage unit. The temperature of 
the burning herb measured by TR-W500 (KEYENCE Co., 
Ltd., Osaka, Japan) was approximately 300 °C. Smoke was 
introduced into the chamber through an aerosol inlet. The 
exhaust flow rate was set at 18 L/min, the aspiration flow rate 
at 1 L/min, and the pressure of exposure cage at −50 Pa. The 
smoke from the pipe was diluted with room air (smoke to 
room air = 1:17) and drawn into the exposure cage at a flow 
rate of 18 L/min. The airflow was stopped 1 min after the 
start of combustion, and the air was left in the chamber for 
another 2 min. Thus, the mice were exposed to the smoke 
for a total of 3 min, followed by fresh air introduced by 
ventilation.
Measurement of chemicals in XLR‑11 smoke
A 0.5-g portion of XLR-11 containing herb was burned, 
and the resulting smoke was introduced to the inhalation 
chamber through the aerosol inlet. The airflow was stopped 
60 s after the start of combustion, and then a 10 mL por-
tion of the chamber air was extracted by a gas-tight syringe 
and absorbed in 1 mL methanol. The mixture was shaken 
in a hermetically sealed vial for 10 min. The solvent was 
evaporated to dryness under a nitrogen stream, and the resi-
due was dissolved in 100 μL methanol. A 20 μL portion 
of that mixture was analyzed by high-performance liquid 
chromatography (HPLC) using the SPD-M10A at 300 nm 
(Shimadzu Co., Kyoto, Japan) and a Prodigy 5µ ODS col-
umn (150 × 4.6 mm, 5 μm particle size; Phenomenex, Tor-
rance, CA, USA). Gradient elution was performed with (A) 
10 mM ammonium acetate and (B) acetonitrile at a flow rate 
of 1 mL/min. The initial elution condition was set at 50% 
B for 20 min and then changed to 100% B for 10 min [9].
Drug treatment
The mice were placed in an activity chamber [200 mm 
(width) × 200 mm (depth) × 250 mm (height)] for 30 min 
prior to drug administration to allow them to become 
acclimated to the environment. AM-251, XLR-11, and 
XLR-11 degradant were dissolved in a 1:1 mixture of etha-
nol and Kolliphor ELP (BASF Japan, Tokyo, Japan) and 
diluted with saline to obtain an ethanol/Kolliphor ELP/
saline vehicle ratio of 1:1:98. Gabapentin was dissolved 
in saline and added to a 1:1 mixture of ethanol and Kolli-
phor ELP to obtain an ethanol/Kolliphor ELP/saline vehi-
cle ratio of 1:1:98. Vehicle (20 mL/kg), XLR-11 (15 mg/
kg), XLR-11 degradant (15 mg/kg), AM-251 (6 mg/kg), 
Fig. 2  Multipurpose inhalation cage unit
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and gabapentin (40 mg/kg) were injected in the mice intra-
peritoneally (i.p.). The  CB1 receptor antagonist AM-251 
and gabapentin were administered 30 min before injecting 
XLR-11 degradant.
Behavioral studies
The mice were anesthetized with a combination of medeto-
midine (0.15 mg/kg), midazolam (2 mg/kg) and butorpha-
nol (2.5 mg/kg). Nano-Tag (Kissei Comtec Co., Matsumoto, 
Japan), an apparatus that measures body temperature and 
locomotor activity, was implanted in the back of the mice at 
least 20 h before initiating the experiments. The locomotor 
activity determined by the Nano-Tag device was defined as 
cross count data, providing counts of the number of times 
crossing the threshold levels from bottom to top per record-
ing interval for the waveform synthesized by the XYZ accel-
eration vectors [12]. The body temperature and locomotor 
activity were analyzed by the Nano-Tag viewer program 
(Kissei Comtec Co.). The bar test was used to measure the 
intensity of catalepsy. Briefly, the forepaws of the mice were 
placed on a metal bar (6 mm diameter) positioned horizon-
tally at a height of 3.5 cm. The time until the mice started 
to move was measured, and the maximum cutoff time was 
set at 90 or 180 s.
In vivo microdialysis for dopamine in the nucleus 
accumbens
Mice, anesthetized with the combination of three anesthet-
ics, were placed in a stereotaxic apparatus. A microdialysis 
probe (D-I-6-01: 0.22 mm outer diameter, 1 mm membrane 
length; Eicom Co., Ltd., Kyoto, Japan) was implanted into 
the nucleus accumbens at the following coordinates; AP: 
+1.76  mm, ML: +0.5  mm relative to bregma and DV: 
−5.0 mm from the skull. The probes were secured to the 
skull using dental acrylic. Mice were provided at least 20 h 
for recovery from surgery before initiating the experiments. 
The probes were perfused at 2 μL/min with artificial cere-
brospinal fluid. Two hours after the reflux, the dialysate sam-
ple was collected in 10-min fractions. Three samples were 
obtained to establish the baseline levels of extracellular DA 
before drug administration, and six samples were obtained 
thereafter. DA levels were measured using an HTEC-500 
HPLC system with an electrochemical detector (Eicom Co., 
Ltd.) and a  C18 reversed-phase column (30 × 4.6 mm i.d., 
Eicompak PP-ODS; Eicom Co., Ltd.) [13, 14]. After the 
microdialysis, the mice were sacrificed and their brains were 
histologically examined to validate the probe placement.
In vivo measurement of extracellular glutamate 
in the hippocampus
Changes in glutamate levels in the hippocampus were evalu-
ated using an enzyme-based biosensor capable of monitor-
ing real-time changes in neurochemical concentrations in 
the brains of freely moving animals (Pinnacle Technology 
Inc., Lawrence, KA, USA). Prior to measurement, the mice 
were anesthetized with sodium pentobarbital (50 mg/kg, 
i.p.) and were placed in a stereotaxic apparatus. A guide 
cannula was implanted in the hippocampus at the follow-
ing coordinates: AP: −2.7 mm, ML: +3.0 mm relative to 
bregma and DV: −1.0 mm from the skull. To connect the 
biosensor to the amplifier for measurement, a head-mount 
device (#8201; Pinnacle Technology Inc.) was placed around 
the recording point and an anchor screw was placed to fix 
the head-mount device. The guide cannula, the screw and 
the head-mount device were covered with dental acrylic. On 
the morning of the day of measurement, the biosensor was 
calibrated. Briefly, the biosensor was placed in a beaker with 
20 mL phosphate-buffered saline (pH 7.4), and the signal 
was measured. After obtaining a stable baseline, the analyte 
(5 mM glutamate stock solution) was injected until the glu-
tamate concentration reached 40 μM. Interference solution 
(100 mM ascorbic acid stock solution) was then added to 
confirm the reaction. After calibration, the mice were anes-
thetized with ether, and the biosensor was inserted into the 
guide cannula and lowered into the recording position. After 
the sensor was connected to the amplifier, the preamplifier 
was plugged into the head-mount device, and the measure-
ment was started. After obtaining a stable baseline of the 
glutamate signal for over 1 h, XLR-11 degradant or vehicle 
was injected intraperitoneally, and the glutamate response 
in the hippocampus was recorded. Data analysis was con-
ducted from 2.5 min before administration to 10 min after 
administration. Biosensor currents were collected at 10-s 
intervals, and the change in glutamate level from the base-
line was measured. The baseline value was defined as the 
signal present 20 s before administration [11]. After each 
experiment, the brain was fixed with 4% paraformaldehyde 
and 30-μm coronal sections were produced by a cryostat 
(Bright Instrument Company, Huntingdon, UK) to verify 
the biosensor position.
Statistical analysis
Body temperature and locomotor activity data were assessed 
using analysis of variance (ANOVA) followed by Tukey’s 
test. The bar test data were analyzed using the Mann-Whit-
ney test. Data from microdialysis experiments and extra-
cellular glutamate levels were analyzed by Welch’s t test 
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and two-way ANOVA followed by the Bonferroni test, 
respectively.
Results
Changes in body temperature and behavior of mice 
exposed to XLR‑11 smoke
Mice were exposed to the smoke produced by burning the 
simulated herbal drug product containing the synthetic 
cannabinoid XLR-11 to observe its psychopharmaco-
logical effects. These effects were monitored using the 
implanted Nano-Tag device, which can detect movements 
in both vertical and horizontal directions. The mice that 
inhaled the herbal smoke containing no drug (control) 
showed no change in their behavior. In contrast, the mice 
that inhaled the drug-containing smoke showed excitatory 
and/or hyperreflexic behavior, such as jumping at the very 
early phase of exposure, followed by suppressive behav-
ior. A significant increase in the locomotor activity, which 
mainly comprised vertical movements such as jumping, 
was observed from 1 to 7 min after XLR-11 smoke expo-
sure (Fig. 3a).
The control mice showed a slight decrease in body tem-
perature over a 5-min period after smoke exposure (Fig. 3b). 
The herbal smoke was introduced into the test cage where 
a mouse was placed in at a flow rate of 18 L/min for 1 min. 
The flow was stopped for 2 min to expose the mouse to the 
smoke. The smoke in the cage was replaced by flesh air 
over the next 2 min, and the chamber lid was then opened. 
Therefore, a mouse was exposed with the airflow for the first 
1 min and last 2 min during 5 min-exposure in the lidded 
cage. Such air blowing may decrease the body temperature. 
The body temperature recovered to the basal level within 
the next 10 min under the circumstances without the airflow 
(Fig. 3b). The mice that inhaled the drug-containing smoke 
showed a significant and a sustainable decrease in the body 
Fig. 3  XLR-11 smoke induced 
transient hyperreflexia (a) 
and hypothermia (b) in mice. 
a Locomotor activity was 
measured every minute from 
5 min before to 20 min after 
XLR-11 smoke exposure using 
an implanted Nano-Tag device. 
The vertical axis represents 
counts per minute (cpm) 
recorded by the three-axis 
sensor. b Body temperature 
was measured every minute 
from 5 min before to 40 min 
after XLR-11 smoke exposure 
using an implanted Nano-Tag 
device. Values represent the 
mean ± standard error of the 
mean (SEM) (n = 6). Statisti-
cal analysis was performed 
using Tukey’s test. *p < 0.05, 
**p < 0.01 vs. control
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temperature starting 7 min after exposure, and the effect 
was most intense after 20 min and lasted for at least 40 min 
(Fig. 3b). These results indicated that the XLR-11 smoke 
induced an excitatory and hyperreflexic effect at the begin-
ning of exposure followed by hypothermia and hypomobil-
ity, which are characteristic effects of synthetic cannabinoids 
[15–17].
XLR‑11 smoke contains XLR‑11 degradant as a main 
ingredient
Reportedly, XLR-11 undergoes a pyrolytic change in its 
chemical structure involving an asymmetric ring opening 
in its tetramethyl cyclopropane ring (Fig. 1a,b) [18]. There-
fore, experiments were conducted to determine the chemi-
cals present in the XLR-11 smoke. The XLR-11 smoke 
was absorbed in methanol and subjected to HPLC analysis 
(Fig. 4c). Two peaks were observed (peaks A and B); reten-
tion time of peak A was considered to be equivalent to that 
of the XLR-11 degradant (Fig. 4b), and peak B was identical 
to that of XLR-11 (Fig. 4a). The calibration curve of XLR-
11 showed linearity between 20 and 200 ng, with a correla-
tion coefficient (r) > 0.999 and regression line y = 57000x. 
The calibration curve of the XLR-11 degradant showed lin-
earity between 200 and 8000 ng, with r > 0.999 and regres-
sion line y = 31700x. These analytical parameters supported 
the quantitative reproducibility. By quantitative analysis, the 
concentrations of XLR-11 and its degradant were calculated 
to be 63.8 and 1640 ng/cm3, respectively, indicating that the 
XLR-11 smoke contained XLR-11 and XLR-11 degradant 
at a ratio of approximately 1:25.
Effects of XLR‑11 and XLR‑11 degradant on body 
temperature and behavior in mice
To clarify whether the excitatory effect of the XLR-11 
smoke in mice is attributed to XLR-11 or XLR-11 degra-
dant, mice were administered XLR-11 degradant i.p. at a 
dose equivalent to that used in the inhalation experiment, 
and the effect was compared with that of the parent com-
pound. Mice treated with XLR-11 degradant (15 mg/kg, i.p.) 
showed excitatory behavior such as jumping at the begin-
ning of the treatment, but mice treated with XLR-11 at a 
dose equivalent to the degradant (15 mg/kg, i.p.) showed 
no such behavior. A significant increase in the locomotor 
activity was observed between 2 and 4 min after XLR-11 
degradant treatment (Fig. 5a) similar to that after XLR-11 
smoke exposure. XLR-11 and XLR-11 degradant induced 
akinesia, determined by the bar test, in mice. Although no 
significant difference was observed between XLR-11 and 
XLR-11 degradant in this experiment when the test duration 
was set at 90 s, the immobility lasted for at least 120 min 
after the treatment (Fig. 5b). XLR-11 showed a significant 
decrease in the body temperature, starting 5 min after the 
treatment and lasting for 90 min. XLR-11 degradant induced 
more potent hypothermia than XLR-11; significant differ-
ences between these compounds were observed at 5 min, 
30 min or later (Fig. 5c). These results suggest that both 
the excitatory and suppressive effects of the XLR-11 smoke 
were mainly caused by XLR-11 degradant.
CB1 mediates XLR‑11 degradant‑induced changes 
in physical responses
Mice were pretreated with the  CB1 receptor antagonist 
AM-251 and treated with XLR-11 degradant to investigate 
the involvement of the  CB1 receptor in the XLR-11 degra-
dant-induced excitatory behavior. An increase in the loco-
motor activity observed 1–4 min after XLR-11 degradant 
treatment was significantly suppressed by AM-251 (Fig. 6a). 
In addition, AM-251 almost completely suppressed the 
immobility (Fig. 6b) and hypothermia (Fig. 6c) induced by 
the XLR-11 degradant. These results indicate that the  CB1 
receptor is involved not only in hypothermia and akinesia 
but also in the excitatory behavior induced by the XLR-11 
degradant.
Effect of XLR‑11 degradant on dopamine levels 
in the nucleus accumbens in mice
DA levels in the nucleus accumbens were measured using 
in vivo microdialysis to investigate whether dopaminergic 
transmission is involved in the excitatory effect of XLR-11 
degradant. Mice were treated i.p. with XLR-11 degradant 
or vehicle, and the extracellular DA levels were determined 
at 10-min intervals. The XLR-11 degradant significantly 
increased the DA levels in the nucleus accumbens between 
10 and 20 min after the treatment (Fig. 7a). However, the 
time when DA levels increased did not coincide with the 
time when the excitatory behavior was observed. Pretreat-
ment with the DA  D1 receptor antagonist SCH23390 (50 μg/
kg, i.p.) or the DA  D2 receptor antagonist sulpiride (50 mg/
kg, i.p.), which have been shown to suppress synthetic cathi-
none-induced psychoactive effects [13], showed no effect on 
the excitatory action of XLR-11 degradant (Fig. 7b). These 
findings suggest that dopaminergic transmission does not 
play a major role in the XLR-11 degradant-induced excita-
tory behavior.
Effect of XLR‑11 degradant on glutamate levels 
in the hippocampus
Glutamate levels in the hippocampus were measured in vivo 
using an enzyme biosensor to investigate whether excessive 
glutamatergic transmission is involved in the excitatory effect 
of XLR-11 degradant. A decrease, in contrast to increase, was 
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observed in the extracellular glutamate levels after XLR-11 
degradant treatment (Fig. 7c). In addition, pretreatment with 
the glutamate receptor (mGlu5) antagonist SIB1757 (4 mg/
kg, i.p.), which has been shown to suppress AM-2201-induced 
seizures [11], showed almost no effect on the excitatory action 
of XLR-11 degradant (Fig. 7d). These results suggest that 
glutamatergic transmission does not play a major role in the 
XLR-11 degradant-induced excitatory behavior.
Fig. 4  High-performance 
liquid chromatography (HPLC) 
chromatograms of XLR-11 (a), 
XLR-11 degradant (b), and 
chamber air (c). XLR-11 (a, 
200 ng) and XLR-11 degradant 
(b, 200 ng) were analyzed by 
HPLC at 300 nm. A 10 mL 
portion of chamber air was 
absorbed in methanol and ana-
lyzed by HPLC (c)
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Effects of gabapentin on XLR‑11 degradant‑induced 
transient behavior
Next, a series of experiments were conducted to inves-
tigate the involvement of GABAergic transmission 
using gabapentin, which increases and maintains the 
GABAergic neuronal function along with inhibiting the 
voltage-dependent calcium channel. Reportedly, gabapen-
tin suppresses pentylenetetrazol-induced seizures at a dose 
of 20 mg/kg (i.p.) [19] and audiogenic seizures at doses 
of 30, 40, and 50 mg/kg (i.p.) [20]. Therefore, gabapen-
tin at a dose of 40 mg/kg (i.p.) was administered 30 min 
before XLR-11 degradant treatment, and the locomotor 
activity was measured. Gabapentin significantly inhib-
ited the XLR-11 degradant-induced excitatory behavior 
between 2 and 3 min after treatment (Fig. 7e), although 
the inhibitory effect seemed to be incomplete. These 
results suggest that impaired GABAergic transmission 
Fig. 5  Effects of XLR-11 and XLR-11 degradant on locomotor activ-
ity (a), catalepsy (b), and body temperature (c) in mice. Mice were 
intraperitoneally (i.p.) treated with vehicle (open circle), XLR-11 
(15  mg/kg, open square), or XLR-11 degradant (15  mg/kg, closed 
square). a Locomotor activity was measured from 5  min before to 
15  min after administration using an implanted Nano-Tag device. b 
The bar test was performed before and 15, 30, 60, 90 and 120  min 
after administration. c Body temperature was measured before and 5, 
15, 30, 60, 90 and 120 min after administration using an implanted 
Nano-Tag device. Values represent the mean ± SEM (n = 6). Sta-
tistical analysis was performed using Tukey’s test (a, c) or the 
Mann–Whitney test (b). *p < 0.05, **p < 0.01 vs. vehicle. #p < 0.05, 
##p < 0.01 vs. XLR-11
Fig. 6  Effects of AM-251 on XLR-11 degradant-induced transient 
hyperreflexia (a), catalepsy (b), and hypothermia (c). AM-251 (6 mg/
kg, i.p.) was administered 30 min before injection of XLR-11 degra-
dant (15 mg/kg, i.p.). Values represent the mean ± SEM (n = 6). Sta-
tistical analysis was performed using Tukey’s test (a, c) or the Mann–
Whitney test (b). *p < 0.05 and **p < 0.01 vs. vehicle. aap < 0.01 vs. 
XLR-11 degradant
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and/or calcium-mediated signal transmission could be 
involved, at least in part, in the excitatory effect of XLR-
11 degradant.
Discussion
Some synthetic cannabinoids were reported to induce a 
generalized seizure in drug abusers immediately after 
smoking [21]. These compounds impart nonselective 
agonistic effects on centrally and peripherally located 
 CB1 and  CB2 receptors, although psychoactive effects 
are mainly mediated via the  CB1 receptor. A recent study 
Fig. 7  Neurotransmission involved in XLR-11 degradant-induced 
transient hyperreflexia. a Mice were administered XLR-11 degradant 
(15 mg/kg, i.p.) or vehicle (10 mL/kg, i.p.) at 0 min, and the dialysate 
was collected every 10 min for 60 min. Extracellular dopamine (DA) 
levels in the nucleus accumbens were analyzed by HPLC–electro-
chemical detection. Basal values of extracellular DA levels in the 
nucleus accumbens were 1.46 ± 0.25 nM (n = 9). Values represent the 
percentage changes (the mean ± SEM, n = 4–5) from the basal levels. 
Statistical analysis was performed using the Welch’s test. *p < 0.05 
vs. vehicle. b Mice were pretreated with SCH23390 (50 μg/kg, i.p.) 
or sulpiride (50  mg/kg, i.p.), and treated with XLR-11 degradant 
(15 mg/kg). Locomotor activity was measured from 5 min before to 
15 min after XLR-11 degradant using an implanted Nano-Tag device. 
c Mice were administered XLR-11 degradant (15 mg/kg) or vehicle at 
0  min. Biosensor currents reflecting glutamate levels were obtained 
every 10 s from 2.5 min before to 10 min after administration. Values 
represent the mean ± SEM (n = 4). Statistical analysis was performed 
using the Bonferroni test. **p < 0.01 vs. vehicle. d, e Mice were pre-
treated with SIB1757 (4 mg/kg, i.p., d) or gabapentin (40 mg/kg, i.p., 
e) and treated with XLR-11 degradant (15 mg/kg). Locomotor activ-
ity was measured from 5 min before to 15 min after administration. 
Values represent the mean ± SEM (n = 5–6). ap < 0.05 vs. XLR-11 
degradant
421Forensic Toxicology (2019) 37:412–423 
1 3
demonstrated that Δ9-THC and JWH-018 induced seizures 
in mice via the  CB1 receptor [22]. It has been reported that 
i.p. injection of XLR-11 causes hypothermia, suppression 
of locomotor activity and induction of catalepsy in mice 
[23, 24]. On the other hand, it has not been reported that 
XLR-11 exhibits excitatory action. In the present study, 
inhalation of the XLR-11 smoke by mice stimulated loco-
motor activity such as jumping, which is known as the 
“popcorn effect” observed after Δ9-THC treatment [25]. In 
addition, the main psychoactive component in the XLR-11 
smoke was found to be XLR-11 degradant produced by 
pyrolysis. The stimulated psychomotor function could be 
likened to the seizures in humans [26, 27] and has been 
shown to be associated with electrographic seizures in 
mice [22]. Therefore, XLR-11 degradant produced dur-
ing smoking may cause seizures in mice and possibly in 
humans as well. It is suggested that the previous studies 
underestimated XLR-11 potency which would increase by 
smoking. This study shows the importance of experimental 
design in line with the actual situation of human abuse. 
The present study also demonstrated that the excitatory 
effect of XLR-11 degradant was mediated mainly through 
the  CB1 receptor, a result consistent with that reported by 
Malyshevskaya et al. [22]. UR-144 (Fig. 1c) is a synthetic 
cannabinoid containing the cyclopropyl ring that forms 
an open ring structure when subjected to pyrolysis [9]. In 
the previous study, this UR-144 degradant (Fig. 1d) also 
showed excitatory effect at the beginning of administra-
tion, and displayed 4-fold higher agonistic activity on the 
 CB1 receptor than UR-144 [9]. Therefore, smoking cer-
tain synthetic cannabinoids leads to greater psychoactive 
effects than inhaling their respective parent compounds.
The synthetic cannabinoids JWH-250 and JWH-073 
cause hyperreflexia and elevated DA levels in the nucleus 
accumbens after administration [10]. Based on this finding, 
DA levels in the nucleus accumbens after XLR-11 degra-
dant administration were measured in the present study by 
microdialysis. The results showed that the onset of excita-
tory behavior did not coincide with the time of increase in 
DA levels (Fig. 7a). These results suggest that an increase 
in DA levels in the nucleus accumbens is not involved in 
the excitatory effect of XLR-11 degradant. Reportedly, the 
synthetic cannabinoid AM-2201 causes seizures in mice 
in the early course of treatment when glutamate levels in 
the hippocampus increase significantly [11]. However, in 
the present study, glutamate levels in the hippocampus 
decreased significantly after XLR-11 degradant administra-
tion (Fig. 7c). This result suggests that the excitatory effect 
of XLR-11 degradant is caused by a mechanism not medi-
ated by glutamate.
This study also demonstrated that gabapentin signifi-
cantly suppressed the enhanced locomotor activity induced 
by XLR-11 degradant (Fig. 7e). The general mechanisms 
underlying the action of gabapentin are as follows: (1) it 
inhibits the release of excitatory neurotransmitters such as 
glutamate, by suppressing the influx of calcium via binding 
to the α2δ-1 auxiliary subunit of the voltage-dependent cal-
cium channel expressed on the presynapse of the excitatory 
nervous system, and (2) it increases the extracellular GABA 
concentration in the brain cortex and activates GABA trans-
porter to maintain/enhance GABAergic function [20, 28]. 
In this study, because glutamate levels in the hippocampus 
significantly decreased, instead of increasing, after XLR-11 
degradant administration, suppressed GABAergic function 
may be involved in the excitatory effect of XLR-11 degra-
dant.  CB1 receptor stimulation has been shown to increase 
 Ca2+ concentration in smooth muscle cells in culture [29]. 
In addition, increased postsynaptic  Ca2+ levels have been 
shown to ultimately cause a transient reduction in the release 
of GABA from  CB1-expressing interneurons [30]. These 
findings suggest that XLR-11 degradant cause a transient 
suppression of GABAergic function in a  CB1 receptor-
dependent manner [31]. Although the overall mechanism of 
synthetic cannabinoid-mediated seizures or excitatory action 
is still unclear,  CB1 receptor-dependent neurotransmission 
and possibly the GABAergic function are likely involved in 
the transient hyperreflexic behavior.
Conclusions
In conclusion, our results indicate that the inhalation of 
XLR-11 smoke, the main active component of which is 
XLR-11 degradant, causes hyperreflexia as well as hypo-
thermia and catalepsy in mice. The XLR-11 degradant is 
more potent than XLR-11, demonstrating the importance of 
this study in line with the actual situation of human abuse. 
This finding further suggests that the hyperreflexic effect of 
XLR-11 degradant is mediated through the  CB1 receptor and 
possibly GABAergic function.
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